Expert Review of Clinical Pharmacology最新文献_第7页

Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia 儿科人群阿片类药物使用障碍：围术期疼痛管理和精确阿片类药物镇痛的注意事项

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-16 DOI: 10.1080/17512433.2024.2343915

Yun Han Chen, Anastasios Xenitidis, Paul Hoffman, Leslie Matthews, Swathi G. Padmanabhan, Lakshmi Aravindan, Ruth Ressler, Inesh Sivam, Sahana Sivam, Chase F. Gillispie, Senthilkumar Sadhasivam

引用次数: 0

Engaging patients in conversations about deprescribing 让患者参与有关取消处方的对话

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-15 DOI: 10.1080/17512433.2024.2343913

Barbara Farrell

引用次数: 0

Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review 通过自发报告系统数据库探索共同暴露时间对信号检测中药物间相互作用的影响：范围综述

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-15 DOI: 10.1080/17512433.2024.2343875

Marianna Cocco, Carla Carnovale, Emilio Clementi, Maria Antonietta Barbieri, Vera Battini, Maurizio Sessa

引用次数: 0

Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities 选择合适的生物制剂治疗中重度斑块状银屑病：合并症的影响

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-11 DOI: 10.1080/17512433.2024.2340552

Laura Mateu-Arrom, Lluis Puig

引用次数: 0

A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy 用于治疗癫痫的氮杂环丁烷概况：从药理学到治疗潜力

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-03 DOI: 10.1080/17512433.2024.2337012

Simona Lattanzi, Eugen Trinka, Stefano Meletti, Pasquale Striano, Sara Matricardi, Mauro Silvestrini, Francesco Brigo

引用次数: 0

Therapeutic drug monitoring of antifungal therapies: do we really need it and what are the best practices? 抗真菌疗法的治疗药物监测：我们真的需要吗？

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-02-21 DOI: 10.1080/17512433.2024.2317293

Johannes Boyer, Martin Hoenigl, Lisa Kriegl

{"title":"Therapeutic drug monitoring of antifungal therapies: do we really need it and what are the best practices?","authors":"Johannes Boyer, Martin Hoenigl, Lisa Kriegl","doi":"10.1080/17512433.2024.2317293","DOIUrl":"10.1080/17512433.2024.2317293","url":null,"abstract":"Introduction: Despite advancements, invasive fungal infections (IFI) still carry high mortality rates, often exceeding 30%. The challenges in diagnosis, coupled with limited effective antifungal options, make managing IFIs complex. Antifungal drugs are essential for IFI management, but their efficacy can be diminished by drug-drug interactions and pharmacokinetic variability. Therapeutic Drug Monitoring (TDM), especially in the context of triazole use, has emerged as a valuable strategy to optimize antifungal therapy.Areas covered: This review provides current evidence regarding the potential benefits of TDM in IFI management. It discusses how TDM can enhance treatment response, safety, and address altered pharmacokinetics in specific patient populations.Expert opinion: TDM plays a crucial role in achieving optimal therapeutic outcomes in IFI management, particularly for certain antifungal agents. Preclinical studies consistently show a link between therapeutic drug levels and antifungal efficacy. However, clinical research in mycology faces challenges due to patient heterogeneity and the diversity of fungal infections. TDM's potential advantages in guiding Echinocandin therapy for critically ill patients warrant further investigation. Additionally, for drugs like Posaconazole, assessing whether serum levels or alternative markers like saliva offer the best measure of efficacy is an intriguing question.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139912437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating clinical pharmacology and artificial intelligence: potential benefits, challenges, and role of clinical pharmacologists. 整合临床药理学和人工智能：潜在的益处、挑战和临床药理学家的作用。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-02-15 DOI: 10.1080/17512433.2024.2317963

Harmanjit Singh, Dwividendra Kumar Nim, Aaronbir Singh Randhawa, Saher Ahluwalia

{"title":"Integrating clinical pharmacology and artificial intelligence: potential benefits, challenges, and role of clinical pharmacologists.","authors":"Harmanjit Singh, Dwividendra Kumar Nim, Aaronbir Singh Randhawa, Saher Ahluwalia","doi":"10.1080/17512433.2024.2317963","DOIUrl":"10.1080/17512433.2024.2317963","url":null,"abstract":"Introduction: The integration of artificial intelligence (AI) into clinical pharmacology could be a potential approach for accelerating drug discovery and development, improving patient care, and streamlining medical research processes.Areas covered: We reviewed the current state of AI applications in clinical pharmacology, focusing on drug discovery and development, precision medicine, pharmacovigilance, and other ventures. Key AI applications in clinical pharmacology are examined, including machine learning, natural language processing, deep learning, and reinforcement learning etc. Additionally, the evolving role of clinical pharmacologists, ethical considerations, and challenges in implementing AI in clinical pharmacology are discussed.Expert opinion: The AI could be instrumental in accelerating drug discovery, predicting drug safety and efficacy, and optimizing clinical trial designs. It can play a vital role in precision medicine by helping in personalized drug dosing, treatment selection, and predicting drug response based on genetic, clinical, and environmental factors. The role of AI in pharmacovigilance, such as signal detection and adverse event prediction, is also promising. The collaboration between clinical pharmacologists and AI experts also poses certain ethical and practical challenges. Clinical pharmacologists can be instrumental in shaping the future of AI-driven clinical pharmacology and contribute to the improvement of healthcare systems.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Centering the patient in decisions about opioid tapering. 在决定阿片类药物减量时以患者为中心。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-02-13 DOI: 10.1080/17512433.2024.2318470

J J Fenton

引用次数: 0

The effect of epilepsy and antiseizure medications on cardiac autonomic functions in children with epilepsy. 癫痫和抗癫痫药物对癫痫患儿心脏自主神经功能的影响。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-02-19 DOI: 10.1080/17512433.2024.2318469

Sherifa Ahmed Hamed, Ali Farrag El Hadad, Mohammed Aboalwafa Aladawy

{"title":"The effect of epilepsy and antiseizure medications on cardiac autonomic functions in children with epilepsy.","authors":"Sherifa Ahmed Hamed, Ali Farrag El Hadad, Mohammed Aboalwafa Aladawy","doi":"10.1080/17512433.2024.2318469","DOIUrl":"10.1080/17512433.2024.2318469","url":null,"abstract":"Background: Autonomic manifestations have been frequently studied in adults with epilepsy. Here, we evaluated cardiac autonomic (ANS) functions in children with epilepsy in the interictal period and determined the risks for their dysfunctions.Research design and methods: This study included 60 patients (boys = 25; girls = 35 age: 14.53 ± 2.54 yrs) and 25 controls. Patients were well-controlled on antiseizure medications (ASMs). The battery of testing included measuring resting heart rate (HR) and blood pressure (BP), 30:15 ratio, HR variability (HRV) response to deep breathing, Valsalva ratio and BP changes in response to standing, isometric exercise and cold.Results: Dizziness was reported in 25%. Autonomic dysfunctions were found in 45% (n = 27). Manifestations included high frequencies of abnormal 30:15 ratio (22%), HRV responses to deep breathing (45%), Valsalava ratio (45%), and BP responses to standing (35%), isometric exercise (27%) and cold (27%), indicating parasympathetic and sympathetic hypofunctions. There were positive correlations between parasympathetic and sympathetic dysfunctions. Logistic analysis showed that the durations of epilepsy and ASMs therapy were associated with ANS dysfunctions [95% CI: 0.895-4.719, p = 0.004].Conclusions: Parasympathetic and sympathetic autonomic hypofunctions are common in children with epilepsy. This could be due to the depressant effect of sodium channel blocker ASMs on central and/or cardiac autonomic systems.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis. 维多珠单抗皮下注射和静脉注射制剂在克罗恩病和溃疡性结肠炎中的暴露-疗效关系。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.1080/17512433.2024.2318465

Geert D'Haens, Maria Rosario, Daniel Polhamus, Nathanael L Dirks, Chunlin Chen, Krisztina Kisfalvi, Christian Agboton, Séverine Vermeire, Brian G Feagan, William J Sandborn

{"title":"Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.","authors":"Geert D'Haens, Maria Rosario, Daniel Polhamus, Nathanael L Dirks, Chunlin Chen, Krisztina Kisfalvi, Christian Agboton, Séverine Vermeire, Brian G Feagan, William J Sandborn","doi":"10.1080/17512433.2024.2318465","DOIUrl":"10.1080/17512433.2024.2318465","url":null,"abstract":"Background and aims: This posthoc analysis of the GEMINI and VISIBLE studies in ulcerative colitis (UC) and Crohn's Disease (CD) assessed exposure-efficacy of vedolizumab intravenous (IV) and subcutaneous (SC).Methods: A previously described population pharmacokinetic model was used to predict average serum and trough concentrations at steady state (Cav,ss, Ctrough,ss) and simulate the transition from vedolizumab IV to SC. Efficacy was defined as clinical remission at week 52: complete Mayo score ≤ 2 points and no individual subscore > 1 point (UC), and CD activity index score ≤ 150 points (CD).Results: Data were from 1968 patients (GEMINI 1 [n = 334], VISIBLE 1 [n = 216], GEMINI 2 [n = 1009], VISIBLE 2 [n = 409]) who received maintenance treatment with vedolizumab IV-Q8W, IV-Q4W, SC-Q2W, or placebo. Model-predicted Cav,ss for IV-Q8W and SC-Q2W was similar in UC and CD. Cav,ss was higher for IV-Q4W than IV-Q8W and SC-Q2W. Ctrough,ss values from IV and SC aligned well with pooled observed Ctrough by treatment group in UC and CD. Cav,ss was equivalent for SC and IV. For UC and CD, efficacy rates were greater in patients in the highest quartiles of vedolizumab exposure for both formulations.Conclusion: Exposure-efficacy relationships for IV and SC vedolizumab administration were comparable, confirming that both are equally effective during maintenance treatment.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0